



Message to the Friedreich Ataxia Community

LX2006 Program Update – Highlights from First Quarter 2026

May 12, 2026

Dear Advocacy Partners and FA community members,

We are pleased to share an [update](#) on LX2006, our investigational gene therapy in Friedreich ataxia (FA), based on highlights from Lexeo's first quarter 2026 results. Over the past quarter, we have made meaningful progress toward LX2006's next phase of development and shared encouraging data from ongoing studies.

Highlights:

Information about Lexeo's interventional gene therapy trial, SUNRISE-FA 2:

- In February, we submitted plans to the U.S. Food and Drug Administration (FDA) for the next phase of our interventional gene therapy trial of LX2006, called SUNRISE-FA 2. We expect to hear feedback from the FDA soon and will share an update once plans are finalized.

Updates about LX2006 presented at a scientific meeting this week (American Society of Gene and Cell Therapy):

- LX2006 data continues to show encouraging signs. People treated with LX2006 have shown improvements in both heart health and neurologic health, including improvement in mean mFARS scores.
- So far, LX2006 has been generally well tolerated, with no serious safety concerns related to treatment reported.
- Early research in animals suggests it may be possible to give LX2006 more than once. In this study, animals first received LX2006 through the bloodstream, followed 8 weeks later by a second dose delivered directly to the brain or spinal fluid. The results indicated that potentially meaningful levels of the treatment were found in the area of the brain important for balance and coordination called the cerebellum, even in the presence of pre-existing antibodies against the vehicle (vector) carrying the gene therapy.

We are grateful to the individuals living with FA, their families, caregivers, investigators, and advocacy partners who make this research possible. We will continue to share updates as we work toward bringing a potential new treatment option to the FA community.

The Lexeo Team